The Filing Desk

Johnson & Johnson

JNJ · NYSE · Health Care · Financials, fiscal 2016 to 2025

JNJ · Last close · November 19, 2026
$267.14
Value Johnson & Johnson yourself

Johnson & Johnson's revenue rose 6.0% to $94.2 billion in fiscal 2025. Its net margin was 28.5%, up from 15.8% a year earlier. Free cash flow was $19.7 billion, down 0.7%. It paid out $18.3 billion in dividends and buybacks, 93% of free cash flow.

Johnson & Johnson Latest fiscal year ended December 28, 2025 10-K filed February 11, 2026 · 0000200406-26-000016 Updated
Revenue
$94.2B
6.0%
Net margin
28.5%
12.6 pts
Net income
$26.8B
90.6%
Free cash flow
$19.7B
0.7%
Return on capital
28.6%
10.1 pts
Market cap
$654.1B
Nov 19 close
P/E
40.5x
On $6.59 EPS, 4 qtrs

Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Total debt is the balance sheet's long-term debt plus its current debt line.

Charts show fiscal years, from the 10-K filings.

What Johnson & Johnson does

Johnson & Johnson makes prescription medicines and medical devices, sold in virtually every country. Its medicines treat cancer, immune diseases such as psoriasis and Crohn's disease, mental illnesses such as depression and schizophrenia, HIV, high blood pressure in the lungs, and blood clots. Its devices include heart pumps and tools for treating irregular heartbeats and clogged arteries, artificial joints and spine products, surgical instruments and staplers, and ACUVUE contact lenses. It sells to wholesalers, distributors, retailers, hospitals and doctors.

Sales were $94.2 billion in 2025. Its medicines segment brought in $60.4 billion, and its MedTech devices segment $33.8 billion. Its biggest product, the multiple myeloma drug DARZALEX, made up about 15.0% of revenue, and STELARA, an immune disease drug now facing competing copies called biosimilars, about 6.5%. It competes with companies large and small, local and global, in every product line, and especially in research to develop new products.

Incorporated in 1887, J&J has about 138,200 employees. In October 2025 it announced plans to separate its orthopaedics business, aiming to finish within 18 to 24 months of the announcement. It also faces many lawsuits, including product liability claims.

Its biggest risks, as it describes them

  • Generic and biosimilar copies of its key drugs, such as STELARA, and challenges to its patents.
  • Healthcare reforms and pricing pressure that could cut what it is paid for its medicines and devices.
  • Large legal cases, including product liability suits, that can bring heavy costs, fines and damage to its reputation.
  • Delays or failures in developing new medicines and devices.
  • The planned separation of its orthopaedics business may not happen as planned or bring the expected results.
From Johnson & Johnson's annual report on Form 10-K, filed February 11, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2016 to 2025, earnings per share grew 7.1% a year and net income 5.5% a year, as buybacks cut the share count by 13%.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments31.622.322.924.520.1
Debt incl. finance leases33.839.729.436.747.9
Net debt (negative means net cash)2.217.46.512.127.8
Net debt to EBITDA0.1x0.7x0.3x0.5x0.7x
Debt to equity0.5x0.5x0.4x0.5x0.6x
Interest coverage105.8x71.1x20.5x23.1x34.5x
Current ratio1.4x1.0x1.2x1.1x1.0x
Quick ratio1.1x0.8x0.9x0.9x0.8x
US$ billions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, billions

Projections

Project Johnson & Johnson's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $257,688 of Johnson & Johnson shares on the open market, and 10 insiders sold $154.4 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 12, 2026Elizabeth ForminardEVP, Chief Legal OfficerSold13,072$284.39$3.7 millionForm 4
Sep 2, 2026Timothy SchmidEVP, WW Chair, MedTechSold33,597$274.74$9.2 millionForm 4
Aug 17, 2026Jennifer L TaubertEVP, WWC. Innovative MedicineSold15,000$263.36$4.0 millionForm 4
Aug 13, 2026Joaquin DuatoCEO and Chairman of the Board, DirectorSold123,291$261.17$32.2 millionForm 4
Aug 6, 2026Elizabeth ForminardEVP, Chief Legal OfficerSold15,918$257.00$4.1 millionForm 4
Aug 5, 2026Joaquin DuatoCEO and Chairman of the Board, DirectorSold48,480$258.15$12.5 millionForm 4
Jul 20, 2026Vanessa BroadhurstEVP, Global Corp AffairsSold23,054$251.27$5.8 millionForm 4
Jun 11, 2026Kathryn E WengelEVP, Chief TO and Risk OfficerSold10,000$241.15$2.4 millionForm 4
Feb 27, 2026Robert J DeckerVP Corporate ControllerSold4,075$247.87$1.0 millionForm 4
Feb 20, 2026Timothy SchmidEVP, WW Chair, MedTechSold1,322$245.66$324,763Form 4
Feb 18, 2026Timothy SchmidEVP, WW Chair, MedTechSold22,623$244.33$5.5 millionForm 4
Feb 17, 2026Joseph J WolkExec VP, CFOSold89,654$242.80$21.8 millionForm 4
The latest 12 of 18 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score7 of 96 of 94 of 9
Rule of 4027.9%26.6%27.0%
Altman Z''4.644.364.67
Accruals ratio7.0%−5.9%1.2%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassFailPass
Cash from operations exceeds net incomeFailPassFail
Debt fell relative to assetsPassFailFail
Current ratio rosePassFailFail
Share count didn't risePassPassPass
Gross margin roseFailPassFail
Revenue rose relative to assetsPassPassFail
F-score7 of 96 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Johnson & Johnson side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Johnson & JohnsonFY256.0%—20.9%28.6%0.7x4
PfizerFY25−1.6%—14.5%7.2%3.2x6Compare
AbbVieFY258.6%24.6%29.1%15.7%2.7x7Compare
ModernaFY25−39.9%−158.1%−106.2%−65.4%—2Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue71.976.581.682.182.678.780.085.288.894.2
Revenue growth2.6%6.3%6.7%0.6%0.6%−4.7%1.6%6.5%4.3%6.0%
Gross profit50.151.054.554.554.255.355.458.661.463.9
Research and development9.110.610.811.412.20.00.00.51.80.1
Operating income——————————
Net income16.51.315.315.114.720.917.935.214.126.8
Diluted EPS (US$)5.930.475.615.635.517.816.7313.725.7911.03
Diluted shares (millions)2,7892,7452,7292,6842,6712,6742,6642,5602,4292,429
Cash flow
Cash from operations18.821.122.223.423.523.421.222.824.324.5
Capital expenditure3.23.33.73.53.33.74.04.54.44.8
Free cash flow15.517.818.519.920.219.817.218.219.819.7
Dividends paid8.68.99.59.910.511.011.711.811.812.4
Share buybacks9.06.45.96.73.23.56.05.12.46.0
Acquisitions4.535.20.95.87.30.117.70.015.117.5
Stock-based compensation0.91.01.01.01.01.11.11.21.21.4
Balance sheet at fiscal year end
Cash and short-term investments41.918.319.719.325.231.622.322.924.520.1
Debt incl. finance leases27.134.630.527.735.233.839.729.436.747.9
Total assets141.2157.3153.0157.7174.9182.0187.4167.6180.1199.2
Total liabilities70.897.193.298.3111.6108.0110.698.8108.6117.7
Shareholders' equity70.460.259.859.563.374.076.868.871.581.5
Margins and ratios
Gross margin69.7%66.7%66.8%66.4%65.6%70.3%69.2%68.8%69.1%67.9%
Operating margin——————————
Net margin23.0%1.7%18.8%18.4%17.8%26.5%22.4%41.3%15.8%28.5%
Free cash flow margin21.6%23.2%22.7%24.3%24.4%25.1%21.5%21.4%22.3%20.9%
Rule of 40 (growth + FCF margin)24.2%29.6%29.4%24.9%25.1%20.4%23.1%27.9%26.6%27.0%
Return on capital31.7%14.1%22.0%22.2%21.1%24.0%19.5%16.5%18.5%28.6%
Return on equity23.4%2.0%25.5%25.4%24.0%30.4%23.8%48.3%20.1%35.0%
Return on assets12.1%0.9%9.9%9.7%8.8%11.7%9.7%19.8%8.1%14.1%
Net debt to EBITDA−0.6x0.7x0.4x0.3x0.4x0.1x0.7x0.3x0.5x0.7x
US$ billions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Johnson & Johnson's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Johnson & Johnson.